0
Orphan Designations
3
FDA Approvals
Latest: RYALTRIS (2022)
0
Active Trials
0
Rare Diseases
0
News (30d)
Quiet
Hikma Specialty USA Inc. is a company with 0 orphan drug designations across 0 rare diseases, including 3 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
No pipeline data available yet.